September Riharb is the Senior Vice President of Marketing at Jeune Aesthetics, Inc. Before joining Jeune, September was the Vice President of Corporate Development at True Digital Surgery where she was responsible for business development and corporate communications. Prior to True Digital Surgery, September served as the Vice President of Marketing at Evolus where she helped lead the Company’s successful IPO and led commercialization of the Company’s flagship neurotoxin product Jeuveau®. Prior to joining Evolus, September served as the Vice President of Development for Allergan where she led the Orbera® Intragastric balloon PMA submission and completed the divestiture of the Health Division. Before working at Allergan, September was a Director of Product Management for Computer Motion, which later merged with Intuitive Surgical, where she was responsible for commercialization of the world’s first surgical robots. She holds a Bachelor of Arts from California State University, Fullerton.
Marc Forth is President and Chief Executive Officer at AEON Biopharma, Inc., a biopharmaceutical company focused on the use of botulinum toxins for the treatment of debilitating medical conditions. Prior to AEON Biopharma, Mr. Forth was the Senior Vice President of Allergan PLC and Division Head for the U.S. Neurosciences, Urology and Medical Dermatology Division. During his 16 year tenure at Allergan, Mr. Forth was responsible for all aspects of the commercialization of both current and future products within Neurosciences, Urology and Medical Dermatology, most notably BOTOX for all therapeutic uses. Prior to Allergan, Mr. Forth held various Sales and Marketing roles of increasing responsibility at TAP Pharmaceuticals Inc., a specialty company focused on Urology, Oncology, Gynecology and Gastroenterology. Mr. Forth received a B.S. in Business Administration from California State University, Fresno and a Graduate Marketing Certification from Southern Methodist University.
Krish Krishnan is the Chairman and CEO at Krystal Biotech. He is an accomplished biotech executive. He was specifically involved in two successful IPOs (COO/CFO of New River Pharmaceuticals, Inc., NASDAQ: NRPH) and COO of Intrexon Corporation, Inc., NYSE:XON), approval of the blockbuster drug Vyvanse (for ADHD in 2007) and the sale of New River Pharmaceuticals, Inc. to Shire Pharmaceuticals, plc for $2.6 billion. He served as the CEO of Pinnacle Pharmaceuticals, Inc. and advanced a potential treatment for urinary tract infection from discovery to Phase II. He has served as Board member for Biotie Therapies Oyi (BTH1V:Helsinki, NASDAQ: BITI), a specialized drug development company in Finland and Thar Pharmaceuticals,Inc. prior to its sale to Grunenthal GmbH in 2017. Previously, Krish served as a Managing Principal of Suppliermarket.com (a pharmaceutical B2B marketplace) that was sold to Ariba in 2001 for $500m. Krish started his career as a Senior Engineer at E.I.Dupont de Nemours. Krish has an undergraduate degree from the Indian Institute of Technology and a graduate degree in Finance from The Wharton School at University of Pennsylvania.
Suma Krishnan is the Founder and COO at Krystal Biotech. She has 25 years of drug development experience and has delivered on multiple gene therapy programs from discovery to the clinic as Head of Therapeutics at Intrexon Corporation (NYSE:XON). Previously, she led the discovery, development, and approval of Vyvanse (blockbuster drug to treat ADHD) as SVP, Product Development at New River Pharmaceuticals. Prior to that, Suma advanced approval of Adderall XR and Fosrenol at Shire. She began her career as a discovery scientist for Janssen Pharmaceuticals, Inc. Suma has over 20 publications and 20 issued US patents. She received her Master of Science in Organic Chemistry from Villanova University, an M.B.A. from Institute of Management and Research, and an undergraduate degree in Organic Chemistry from Ferguson University.